drugset / Trial / NCT00282399
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to determine which of the doses of decitabine maximizes genomic demethylation in patients with Myelodysplastic Syndrome (MDS).
Timeline
- Start
- 2006-10
- Primary completion
- 2008-10
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 2 mg/m2 | Subcutaneous |
| Subject | Decitabine | Small molecule | 5 mg/m2 | Subcutaneous |
| Subject | Decitabine | Small molecule | 10 mg/m2 | Subcutaneous |